Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: Understanding the CML Patient Experience" report has been added to ResearchAndMarkets.com's offering.
This 89-page Chronic Myeloid Leukemia (CML) in America report provides a comprehensive look at life for those living with chronic myeloid leukemia. Using detailed quantitative data, it gives a full picture of the CML patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges.
The 5-year relative survival rate for a CML patient is just under 70% and about 9,000 people are diagnosed with CML every year in the US.
Chronic Myeloid Leukemia (CML) in America 2023: Understanding the CML Patient Experience offers an in-depth look at the CML patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the CML patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more.
What makes this report unique?
Very simply: the analyst's focus on patients. This syndicated report is one of the few studies that is based on primary research with diagnosed patients, bringing the patient voice to the forefront.
Valuable insights. Informed decisions.
This report lifts the curtain on life with CML, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs.
This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost.
The analyst is a proven leader in understanding the experiences of people living with chronic health conditions. Through their portfolio of 45+ condition-specific online health communities, they reach millions of individuals, offering information, connection, and support to patients and caregivers in the U.S.
This report includes a deep-dive into:
- CML patient demographics
- Age, gender, ethnicity, marital status, children, employment status, income, location, insurance, and other health conditions
- Impact of CML on quality of life
- Time since diagnosis, remission status, impact on quality of life, symptoms experienced, and what patients wish others better understood
- Information-seeking behaviors
- Information sources used, plus topics of interest
- HCP engagement
- Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used
- CML treatment awareness and experiences
- Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials
Key questions answered in this report:
- To what extent do people say CML impacts their overall quality of life?
- What percentage of patients have received 3+ courses of treatment?
- What do patients wish others understood about CML?
- What percentage of patients see a specialist for CML treatment?
- What treatments have the highest aided brand awareness among patients?
- What percentage of patients have used targeted therapy or immunotherapy?
- How many patients feel their CML is well-controlled on their current treatment plan?
- What percentage of patients are likely to switch or add new treatments in the next six months?
- What medications have patients discussed with their HCP?
- What are the top online resources people with CML use to find information?
- What kinds of content and information do patients search for?
- What percentage of patients search for information on treatment options?
Methodology
- The report consists of:
- A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions
- Qualitative patient insights from open-ended responses
Additional details:
- Fielded: January 16, 2023 to April 14, 2023
- Convenience sample of 91 respondents diagnosed with CML
- Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners
Key Topics Covered:
Methodology
Respondent Demographics
Research Highlights
Condition Status and Quality of Life
- CML Diagnosis and Remission
- Symptoms Experienced
- Impact on Quality of Life
- Qualitative Patient Insights
Information-Seeking Behaviors
- Resources Used to Manage Health
- Types of Content/Information Sought
Treatment Awareness and Experiences
- Primary HCP Seen for CML Care
- Aided Brand Awareness of Treatments
- Treatment Usage
- Condition Control on Current Treatment and Clinical Trial Interest
- Treatment Discussions with HCP
Appendix with All Data Charts and Distributions
Products Mentioned
- BOSULIF (bosutinib)
- GLEEVEC (imatinib mesylate)
- ICLUSIG (ponatinib)
- SCEMBLIX (asciminib)
- SPRYCEL (dasatinib)
- SYNRIBO (omacetaxine mepesuccinate)
- TASIGNA (nilotinib)
For more information about this report visit https://www.researchandmarkets.com/r/9b3b5u
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
